Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Total Current Liabilities (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Total Current Liabilities for 10 consecutive years, with $384.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Current Liabilities rose 11.63% to $384.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $384.0 million, a 11.63% increase, with the full-year FY2025 number at $384.0 million, up 11.63% from a year prior.
  • Total Current Liabilities was $384.0 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $340.0 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $384.0 million in Q4 2025 to a low of $127.0 million in Q1 2021.
  • A 5-year average of $245.1 million and a median of $249.8 million in 2023 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: crashed 35.46% in 2021, then surged 73.64% in 2022.
  • Ultragenyx Pharmaceutical's Total Current Liabilities stood at $181.4 million in 2021, then soared by 44.02% to $261.2 million in 2022, then increased by 7.36% to $280.4 million in 2023, then increased by 22.67% to $344.0 million in 2024, then rose by 11.63% to $384.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Total Current Liabilities are $384.0 million (Q4 2025), $340.0 million (Q3 2025), and $293.2 million (Q2 2025).